Press release
Increasing Cases Of Genetic Disorders Are Expected To Drive Growth In The Fabrazyme Market: Major Factor in the Transformation of the Fabrazyme Market in 2025
How Will the Fabrazyme Market Grow, and What Is the Projected Market Size?The market size of Fabrazyme has seen impressive growth in recent years. The market valuation is anticipated to surge from $1,103.73 million in 2024 to $1,256.07 million in 2025, representing a compound annual growth rate (CAGR) of 13.8%. The growth recorded in the past years can be credited to heightened awareness about Fabry disease, progress in enzyme replacement therapy (ERT), a surge in the prevalence of Fabry disease, innovative drug formulations, and substantive investment in research and development.
The market size of fabrazyme is anticipated to experience swift expansion in the ensuing years. It's projected to rise to $2,079.55 million in 2029 with a compound annual growth rate (CAGR) of 13.4%. The surge during the forecasted phase can be credited to the increasing awareness about Fabry disease, progress in genetic testing, an expanding patient population, regulatory backing and reimbursement policies, as well as a focus on rare diseases. The forecasted period will also see major trends like growing diagnosis rates, advancements in technology, expansion into emerging markets, efforts towards sustainability, and a shift towards digital transformation.
What Key Elements Are Boosting Growth in the Fabrazyme Market?
The fabrazyme market is expected to witness significant growth due to the escalating instances of genetic disorders. These disorders are primarily health conditions resulting from abnormalities in a person's genetic material. Advanced diagnostic technologies, environmental influences, lifestyle changes, and late parenthood are among the reasons for the rise in such disorders. Fabrazyme, a form of enzyme replacement therapy, assists those suffering from Fabry disease - a genetic disorder triggered by a deficiency of the enzyme alpha-galactosidase A. The therapy provides the deficient enzyme to decompose specific lipids that have accumulated in the body, reducing the possibility of organ damage, lessening symptoms, and enhancing the overall quality of life. For example, as per statistics from the UK-based registered charity, Gene People, in March 2024, over 6,000 genetic conditions were diagnosed in the UK affecting roughly 1 in 25 children. This has resulted in about 30,000 new diagnoses each year, and more than 2.4 million individuals currently living with a genetic condition. Consequently, the increase in genetic disorders is driving the fabrazyme market. Additionally, the growth of the fabrazyme market can be significantly attributed to the rising healthcare expenditure. This surge in expenditure on health services and related activities is due to factors like an ageing population, chronic diseases, increased demand, higher service prices, rising drug costs, technological advancements, the impact of COVID-19, medical inflation, and income polarization. With the aid of healthcare expenditure, Fabrazyme presents an efficient solution to managing Fabry disease. It cuts down on the need for expensive emergency interventions and long-term treatments, leading to improved patient outcomes and justifying its investment in the healthcare system. For example, data from the US-based National Library of Medicine stated in December 2023 that the U.S. healthcare spending grew by 4.1% in 2022, reaching $4.5 trillion which was a faster increase than the 3.2% growth observed in 2021. Accordingly, escalating healthcare expenditure is propelling the growth of the fabrazyme market.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19903&type=smp
Who Are the Major Industry Players Fueling Fabrazyme Market Expansion?
Major companies operating in the fabrazyme market include Sanofi S.A., JCR Pharmaceuticals, mAbxience
How Is the Segmentation of the Fabrazyme Market Defined?
The fabrazymemarket covered in this report is segmented -
1) By Type: 5mg/vial; 35mg/vial
2) By Indication: Fabry Disease; Renal Impairment; Cardiac Involvement; Neuropathic Pain; Stroke Prevention
2) By Application: Hospital; Drug store
3) By End-User: Pediatric; Adult
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/fabrazyme-global-market-report
What Is the Leading Region in the Fabrazyme Market?
North America was the largest region in the Fabrazyme market in 2024. The regions covered in the fabrazyme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Is Covered In The Fabrazyme Global Market Report?
- Market Size Analysis: Analyze the fabrazyme Market Size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the fabrazyme market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall fabrazyme market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the fabrazyme market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19903
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Increasing Cases Of Genetic Disorders Are Expected To Drive Growth In The Fabrazyme Market: Major Factor in the Transformation of the Fabrazyme Market in 2025 here
News-ID: 3874043 • Views: …
More Releases from The Business Research Company
Comprehensive Insights Into The Global Electric Bikes And Scooters Market: Key G …
The electric bikes and scooters report outlines and analyzes the electric bikes and scooters (excluding e-mopeds or 2-wheelers) market, covering the historic period 2019-2024 and the forecast period 2024-2029 and 2034F. The study examines the market across all regions and major regional economies.
The global electric bikes and scooters (excluding e-mopeds or 2 wheelers) market was valued at approximately $43.09310 billion in 2024, reflecting a CAGR of 12.12% since 2019. The…
Geothermal Heat Pump Market Report 2025: Size, Trends, and Key Growth Insights f …
The geothermal heat pump report outlines and analyzes the geothermal heat pump market, covering 2019-2024 as the historic period and 2024-2029, 2034F as the forecast period. The report examines the market across every region and assesses major economies within each region.
The global geothermal heat pump market reached $4.40620 billion in 2024, increasing at a CAGR of 5.70% since 2019. The market is projected to grow from $4.40620 billion in 2024…
Major Growth Driver Identified in 2025 VFX In Advertising Market: The Rise Of So …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
VFX In Advertising Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
Over the past several years, the market size of vfx in advertising has seen robust growth. It is expected to expand from $2.8 billion in 2024 to a staggering $3.03 billion in 2025, exhibiting…
Driving Web Content, Search Portals And Social Media Market Growth in 2025: The …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Web Content, Search Portals And Social Media Market Size Growth Forecast: What to Expect by 2025?
The market size for web content, search portals, and social media has seen quick expansion in the past few years. It's projected to expand from $682.14 billion in 2024 to $768.29 billion in…
More Releases for Fabrazyme
Fabry Disease Market Analysis: Epidemiology Insights, Therapies, Companies, by D …
The Fabry Disease Treatment Market Size was valued ~USD 1,700 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034).
Emerging therapies for Fabry Disease, including Venglustat, Isaralgagene civaparvovec (ST-920), AMT-191, and others, are anticipated to drive market growth in the coming years.
DelveInsight has released a new report, "Fabry Disease - Market Insights, Epidemiology, and Market Forecast 2034," providing comprehensive insights into the disease,…
Fabrazyme Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and …
Which drivers are expected to have the greatest impact on the over the fabrazyme market's growth?
The growth of the fabrazyme market is anticipated to be driven by the escalating cases of genetic disorders. Genetic disorders, which are health conditions stemming from abnormalities in individual genetic material, are on the rise due to advanced diagnostic technologies that are identifying more cases and factors like delayed parenthood, environmental influences, and lifestyle changes…
Fabrazyme (agalsidase beta) Market Size, Insights 2031 by Key Vendors- Genzyme C …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: According to Verified Market Reports analysis, the global Fabrazyme (agalsidase beta) Market size was valued at USD 1.14 Billion in 2023 and is projected to reach USD 3.6 Billion by 2031, growing at a CAGR of 7.9% during the forecasted period 2024 to 2031.
What is the current outlook for the Fabrazyme (agalsidase beta) Market?
The Fabrazyme (agalsidase beta) market is positioned for moderate growth, driven by its critical…
Fabrazyme Market Size and Share Analysis Across 7MM and Competitive Landscape by …
DelveInsight has released a comprehensive report titled "Fabrazyme Market Forecast" offering a thorough examination and predictive insights into the Fabrazyme market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of Fabrazyme in the therapeutics landscape for Fabry Disease across the 7MM,…
FABRAZYME Drug Market Forecast and Analysis | FABRAZYME for Fabry Disease: Marke …
(Albany, United States)//- The FABRAZYME market forecast report provides an analysis of the FABRAZYME market analysis and forecasts up to 2032 in the seven major markets (7MM). The comprehensive report provides an analysis of FABRAZYME market potential and FABRAZYME market share analysis in Fabry Disease across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan from 2019 to 2032.
The report also helps you to…
Fabry Disease Treatment Market Industry Share, Size: 2021 Market Research with G …
Fabry Disease Treatment Market size is projected to experience significant growth from 2021 to 2027.
Fabry disease is a rare acquired lysosome stockpile problem caused by genetic modifications that interfere with the dose of the alpha-galactosidase protein. Most Fabry diseases start with mild symptoms and start late, so a few patients are not found often. The disease committee’s criterion for consideration is catalytic replacement treatment (ERT). Sanofi’s Fabrazyme and Shire’s Replagal are…
